Table 2 Baseline characteristics of the study patients by group
| Â | Placebo group (n= 32) | Atorvastatin group (n= 28) | P |
|---|---|---|---|
Age (years) | 41.4 ± 12.4 | 41.8 ± 13.4 | ns |
Gender (females/males) | 30/2 | 24/4 | ns |
Arterial hypertension (n (%)) | 2 (6.3%) | 1 (3.6%) | ns |
Diabetes mellitus (n (%)) | 0 (0%) | 0 (0%) | ns |
Obesity (n (%)) | 0 (0%) | 0 (0%) | ns |
Tobacco smoking (n (%)) | 1 (3.1%) | 1 (3.6%) | ns |
Total cholesterol (mmol/l) | 4.5 ± 0.8 | 5.1 ± 1.2 | ns |
LDL cholesterol (mmol/l) | 2.6 ± 0.8 | 2.9 ± 1.0 | ns |
HDL cholesterol (mmol/l) | 1.4 ± 0.3 | 1.4 ± 0.3 | ns |
Triglycerides (mmol/l) | 1.2 ± 0.5 | 1.6 ± 0.6 | < 0.05 |
CRP (mg/l) | 4.0 ± 8.9 | 4.4 ± 4.1 | ns |
Number of patients with plaques in MDCT (n (%)) | 9 (28.1%) | 6 (21.4%) | ns |
Plaque volume (mm3) | 35.2 ± 44.9 | 54.5 ± 62.4 | ns |
Calcium score | 32.1 ± 39.1 | 44.8 ± 50.6 | ns |
Number of patients with perfusion defects in SPECT | 18 (56.3%) | 12 (42.9%) | ns |
Number of underperfused myocardial segments (median) | 3 (9.4%) | 3 (10.7%) | ns |